GS-19

N/A

Report date: 2025/03/18 15:02:43

Base Information

Drug NameGS-19
Drug Alias NameGT-90008GS-19GS-19-PLB-1C
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta inhibitors
TargetsProgrammed death-ligand 1Transforming growth factor beta
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGensun Biopharma Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Koshine Biomedica IncSuzhou Zelgen Biopharmaceuticals Co LtdKaifa Pharmaceutical (Guangdong) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A